Durability of tetanus seroprotection in people living with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
26
2
2022
medline:
12
7
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
The aim of this study was to estimate the durability of tetanus toxoid specific seroprotection in a cohort of people with HIV (PWH). A cross-sectional study. PWH with a last date of tetanus toxoid booster available were identified. Tetanus toxoid specific IgG were detected using commercial ELISA kit. Durability of seroprotection was estimated using a linear regression model and analyzed according to the country of birth. The impact of baseline parameters at the time of vaccination (CD4 + T cell count, viral load, and antiretroviral therapy) was also assessed. One hundred three individuals were included. The median duration between last tetanus toxoid booster and sampling was 5.6years (IQR 2.6-8.9). Using a linear regression model, half-life of tetanus toxoid specific antibody was estimated at 9.9 years [95% confidence interval (95% CI: 5.5-50)] in the whole cohort. Half-life was reduced in individuals born outside Europe: 4.4 years (95% CI: 2.9-8.5). PWH born outside Europe had lower CD4 + T cell count at the time of immunization and more frequently a CD4 + T cell count nadir less than 200 cells/μl before vaccination. PWH born outside Europe have lower half-life of tetanus toxoid specific antibody as compared to previous study performed in the general population. Possible causes include lower nadir or current CD4 + T cell count or under-immunization status in country of origin before migration. Longer interval of booster vaccination, as recommended in the general population, might not be appropriate in this subgroup of PWH. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Identifiants
pubmed: 35212671
doi: 10.1097/QAD.0000000000003206
pii: 00002030-900000000-96211
doi:
Substances chimiques
Antibodies, Bacterial
0
Tetanus Toxoid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1135-1139Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Kerneis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boelle P-Y. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis . Clin Infect Dis 2014; 58:1130–1139.
Roper MH, Wassilak SGF, Tiwari TSP, Orenstein WA. Tetanus toxoid. Vaccines. Philadelphia, Pennsylvania: Elsevier; 2013, 746–772.
Hammarlund E, Thomas A, Poore EA, Amanna IJ, Rynko AE, Mori M, et al. Durability of vaccine-induced immunity against tetanus and diphtheria toxins: a cross-sectional analysis . Clin Infect Dis 2016; 62:1111–1118.
Ferlito C, Biselli R, Mariotti S, von Hunolstein C, Teloni R, Ralli L, et al. Tetanus-diphtheria vaccination in adults: the long-term persistence of antibodies is not dependent on polyclonal B-cell activation and the defective response to diphtheria toxoid revaccination is associated to HLADRB1 ∗ 01 . Vaccine 2018; 36:6718–6725.
Borella-Venturini M, Frasson C, Paluan F, De Nuzzo D, Di Masi G, Giraldo M, et al. Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers . Epidemiol Infect 2017; 145:1757–1762.
World Health Organization. Tetanus vaccines: WHO position paper-February 2017 . Wkly Epidemiol Rec 2017; 92:53–76.
Slifka AM, Park B, Gao L, Slifka MK. Incidence of tetanus and diphtheria in relation to adult vaccination schedules . Clin Infect Dis 2021; 72:285–292.
Bonetti TCS, Succi RCM, Weckx LY, Tavares-Lopes L, de Mor-aes-Pinto MI. Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women . Vaccine 2004; 22:3707–3712.
Dieye TN, Sow PS, Simonart T, Gueye-Ndiaye A, Popper SJ, Delforge ML, et al. Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals . Vaccine 2001; 20:905–913.
Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, et al. British HIV association guidelines on the use of vaccines in HIV-positive adults 2015 . HIV Medicine 2016; 17:S2–S81.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support . J Biomed Inform 2009; 42:377–381.
R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017. http://www.r-project.org/ .
Dauby N. Perinatal HIV and response to vaccination . AIDS 2019; 33:1674–1675.
Mosser JF, Gagne-Maynard W, Rao PC, Osgood-Zimmerman A, Fullman N, Graetz N, et al. Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study . The Lancet 2019; 393:1843–1855.
Dalal S, Samuelson J, Reed J, Yakubu A, Ncube B, Baggaley R. Tetanus disease and deaths in men reveal need for vaccination . Bull World Health Organ 2016; 94:613–621.
Mipatrini D, Stefanelli P, Severoni S, Rezza G. Vaccinations in migrants and refugees: a challenge for European health systems. A systematic review of current scientific evidence . Pathog Glob Health 2017; 111:59–68.
Mullaert J, Abgrall S, Lele N, Batteux F, Slama LB, Meritet J-F, et al. Diphtheria, tetanus, poliomyelitis, yellow fever and hepatitis B seroprevalence among HIV1-infected migrants. Results from the ANRS VIHVO vaccine sub-study . Vaccine 2015; 33:4938–4944.
Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine . J Clin Invest 2014; 124:3147–3158.
Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus . Clin Infect Dis 1995; 21:1197–1203.
Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian R, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection . AIDS 2003; 17:2015–2023.